Impact of Peri-Transplant Weight Loss on Overall Survival in Allogeneic Hematopoietic Stem Cell Transplant

The present work was performed to investigate the association between peri-transplant weight loss and the overall survival (OS) of patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Data from 310 adults who were diagnosed with acute leukemia and underwent allo-HSCT between March 2001 and December 2011 were analyzed. Demographic and clinical data were collected from medical records. Weight loss was categorized into to “no weight loss”, 0≤ 5%weight loss and >5% weight loss, respectively. Cox proportional hazards models was used to estimate hazard ratios with 95% confidence intervals. The median follow-up time among the patients was 19.5 months (interquartile range=7.6 to 37.7). A total of 93 (34.4%) people died within the follow-up period. For the overall comparison of probabilities of OS, there were no statistically significant difference among the weight change groups (P=0.732), corresponding OS probabilities at 3 years were 70.3% [56.5%-84.1%], 76.2% [67.4%-85%], and 76.5% [68.5%-84.5%], respectively. After adjustment the potential confounders, patients who had weight loss ≤ 5% and >5%weight loss did not have poor OS compared with patients who had no weight loss (HR=1.31, 95% CI: 0.70–2.45, HR=0.96, p=0.394; 95% CI: 0.52-1.79, p=0.896). We did not find an association between peri-transplant weight loss and OS in allo-HSCT patients. Further study will be needed to explore the effects of weight loss on allo-transplant patients. Demographic and clinical data were collected from medical records. Weight loss was categorized into to “no weight loss”, 0≤ 5%weight loss and >5%weight loss, respectively. Cox proportional hazards models was used to estimate hazard ratios with 95% confidence intervals. The median follow-up time among the patients was 19.5 months (interquartile range=7.6 to 37.7). A total of 93 (34.4%) people died within the follow-up period. For the overall comparison of probabilities of OS, there were no statistically significant difference among the weight change groups (P=0.732), corresponding OS probabilities at 3 years were 70.3% [56.5%84.1%], 76.2% [67.4%-85%], and 76.5% [68.5%-84.5%], respectively. After adjustment the potential confounders, patients who had weight loss ≤ 5% and >5%weight loss did not have poor OS compared with patients who had no weight loss (HR=1.31, 95% CI: 0.70–2.45, HR=0.96, p=0.394; 95% CI: 0.52-1.79, p=0.896). We did not find an association between peri-transplant weight loss and OS in allo-HSCT patients. Further study will be needed to explore the effects of weight loss on allo-transplant patients.